{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:29:37Z","timestamp":1771270177362,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF19OC0058501"],"award-info":[{"award-number":["NNF19OC0058501"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Doxorubicin is a widely used chemotherapeutic drug that can be administered intravenously as both a bolus infusion and a continuous infusion. The latter is believed to lower the risk of cardiotoxicity, which is a critical long-term complication of doxorubicin treatment. The local tissue concentrations of doxorubicin will be reflected in both treatment efficacy and toxicity, but very limited information is available. The aim of this study was to measure the concentration of doxorubicin after continuous and bolus infusion in tissue compartments around a typical location of a bone tumour.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sixteen pigs (female, Danish Landrace, mean\u00a0weight 77\u00a0kg) were randomized into two groups of eight. Both groups received an intravenous infusion of 150\u00a0mg doxorubicin; Group 1 received a bolus infusion (10\u201315\u00a0min) and Group 2 received a continuous infusion (6\u00a0h). Before infusion, microdialysis catheters were placed intravenously and in four bone tumour-relevant tissue compartments (cancellous bone, subcutaneous tissue, synovial fluid of the knee joint and muscle tissue). Sampling was done (<jats:italic>n<\/jats:italic>\u2009=\u200915) over 24\u00a0h, and venous blood samples were collected as a reference.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Area under the concentration\u2013time curve (AUC<jats:sub>0\u201324\u00a0h<\/jats:sub>) for plasma (total concentration) was significantly different between the two groups, while peak drug concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>) was significantly higher in two compartments (plasma and synovial fluid of the knee joint) in Group 1 compared to Group 2. Overall, the unbound tissue concentrations were extremely low with values below 0.20\u00a0\u00b5g\/mL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The pharmacokinetic profile for doxorubicin in the investigated tissues is very similar when comparing bolus and 6\u00a0h continuous infusion.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-023-04637-1","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T19:02:41Z","timestamp":1707418961000},"page":"555-564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study"],"prefix":"10.1007","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6334-3164","authenticated-orcid":false,"given":"Andrea Ren\u00e9","family":"J\u00f8rgensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7215-8323","authenticated-orcid":false,"given":"Mats","family":"Bue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6845-1874","authenticated-orcid":false,"given":"Pelle","family":"Hanberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5164-5197","authenticated-orcid":false,"given":"Elisabeth Krogsgaard","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7255-9557","authenticated-orcid":false,"given":"Christina","family":"Harlev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4115-2858","authenticated-orcid":false,"given":"Jakob","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4826-8412","authenticated-orcid":false,"given":"Thomas","family":"Baad-Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6020-2320","authenticated-orcid":false,"given":"Akmal","family":"Safwat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-2075","authenticated-orcid":false,"given":"Maiken","family":"Stilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"4637_CR1","unstructured":"L\u00e6gemiddelstyrelsen, PRODUKTRESUM\u00c9 for Doxorubicin \u201dActavis\u201d, koncentrat til infusionsv\u00e6ske, opl\u00f8sning. 12.09.2022: http:\/\/produktresume.dk\/AppBuilder\/search?utf8=\u2713&id=&type=&q=doxorubicin&button=S\u00f8g."},{"key":"4637_CR2","doi-asserted-by":"crossref","unstructured":"Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80(2): 249\u201359","DOI":"10.7326\/0003-4819-80-2-249"},{"issue":"3","key":"4637_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00280-022-04400-y","volume":"89","author":"RE Nicoletto","year":"2022","unstructured":"Nicoletto RE, Ofner CM 3rd (2022) Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemother Pharmacol 89(3):285\u2013311","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4637_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G et al (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185\u2013229","journal-title":"Pharmacol Rev"},{"issue":"1","key":"4637_CR5","first-page":"84","volume":"1845","author":"F Yang","year":"2014","unstructured":"Yang F et al (2014) Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 1845(1):84\u201389","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"4637_CR6","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.2174\/092986709788186228","volume":"16","author":"A Mordente","year":"2009","unstructured":"Mordente A et al (2009) New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 16(13):1656\u20131672","journal-title":"Curr Med Chem"},{"issue":"2","key":"4637_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","volume":"96","author":"SS Legha","year":"1982","unstructured":"Legha SS et al (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96(2):133\u2013139","journal-title":"Ann Intern Med"},{"key":"4637_CR8","doi-asserted-by":"crossref","unstructured":"van Dalen EC, van der Pal HJ, Kremer LC (2016) Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev 3(3): Cd005008","DOI":"10.1002\/14651858.CD005008.pub4"},{"issue":"3","key":"4637_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00685716","volume":"27","author":"JM Jacquet","year":"1990","unstructured":"Jacquet JM et al (1990) Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 27(3):219\u2013225","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4637_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/clpt.1993.69","volume":"53","author":"SC Piscitelli","year":"1993","unstructured":"Piscitelli SC et al (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53(5):555\u2013561","journal-title":"Clin Pharmacol Ther"},{"issue":"3\u20134","key":"4637_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ejps.2010.07.015","volume":"41","author":"DR Barpe","year":"2010","unstructured":"Barpe DR, Rosa DD, Froehlich PE (2010) Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci 41(3\u20134):458\u2013463","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"4637_CR12","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1002\/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0","volume":"39","author":"RM O\u2019Bryan","year":"1977","unstructured":"O\u2019Bryan RM et al (1977) Dose response evaluation of adriamycin in human neoplasia. Cancer 39(5):1940\u20131948","journal-title":"Cancer"},{"issue":"8","key":"4637_CR13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1200\/JCO.2008.20.2267","volume":"28","author":"M Tukenova","year":"2010","unstructured":"Tukenova M et al (2010) Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28(8):1308\u20131315","journal-title":"J Clin Oncol"},{"issue":"1","key":"4637_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10565-006-0142-9","volume":"23","author":"J Robert","year":"2007","unstructured":"Robert J (2007) Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol 23(1):27\u201337","journal-title":"Cell Biol Toxicol"},{"issue":"5","key":"4637_CR15","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1007\/s12035-016-9929-8","volume":"54","author":"CM Kho","year":"2017","unstructured":"Kho CM et al (2017) A review on microdialysis calibration methods: the theory and current related efforts. Mol Neurobiol 54(5):3506\u20133527","journal-title":"Mol Neurobiol"},{"issue":"5","key":"4637_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s11095-006-9206-z","volume":"24","author":"CS Chaurasia","year":"2007","unstructured":"Chaurasia CS et al (2007) AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res 24(5):1014\u20131025","journal-title":"Pharm Res"},{"key":"4637_CR17","unstructured":"Shippenberg TS, Thompson AC (2001) Overview of microdialysis. Curr Protoc Neurosci Chapter 7: Unit7.1"},{"key":"4637_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115872","volume":"239","author":"AR J\u00f8rgensen","year":"2024","unstructured":"J\u00f8rgensen AR et al (2024) Microdialysis as a sampling tool for the chemotherapeutic agent Doxorubicin. J Pharm Biomed Anal 239:115872","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"4637_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/0300985811402846","volume":"49","author":"MM Swindle","year":"2012","unstructured":"Swindle MM et al (2012) Swine as models in biomedical research and toxicology testing. Vet Pathol 49(2):344\u2013356","journal-title":"Vet Pathol"},{"key":"4637_CR20","unstructured":"Bollen PJAea. The Laboratory Swine [cited 2022 09.09]. Available from https:\/\/books.google.dk\/books?id=TU3RBQAAQBAJ&printsec=frontcover&hl=da#v=onepage&q=body&f=false"},{"key":"4637_CR21","unstructured":"Genomics of drug sensitivity in cancer [cited 2022 10.06.22]. Available from https:\/\/www.cancerrxgene.org\/compound\/Doxorubicin\/133\/overview\/ic50?"},{"key":"4637_CR22","unstructured":"Genomics of Drug Sensitivity in Cancer [cited 2023 20.06]. Available from https:\/\/www.cancerrxgene.org\/compound\/Doxorubicin\/133\/overview\/ic50?"},{"issue":"6","key":"4637_CR23","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/bjc.1980.165","volume":"41","author":"H Eichholtz-Wirth","year":"1980","unstructured":"Eichholtz-Wirth H (1980) Dependence of the cytostatic effect of adriamycin on drug concentration and exposure time in vitro. Br J Cancer 41(6):886\u2013891","journal-title":"Br J Cancer"},{"issue":"11","key":"4637_CR24","first-page":"2991","volume":"34","author":"CM Haskell","year":"1974","unstructured":"Haskell CM, Sullivan A (1974) Comparative survival in tissue culture of normal and neoplastic human cells exposed to adriamycin. Cancer Res 34(11):2991\u20132994","journal-title":"Cancer Res"},{"issue":"1","key":"4637_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00685876","volume":"32","author":"BJ Cusack","year":"1993","unstructured":"Cusack BJ et al (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32(1):53\u201358","journal-title":"Cancer Chemother Pharmacol"},{"key":"4637_CR26","first-page":"77","volume":"3","author":"DE Brenner","year":"1984","unstructured":"Brenner DE et al (1984) Human plasma pharmacokinetics of doxorubicin: comparison of bolus and infusional administration. Cancer Treatment Symposia 3:77\u201383","journal-title":"Cancer Treatment Symposia"},{"issue":"6","key":"4637_CR27","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1200\/JCO.2002.20.6.1677","volume":"20","author":"SE Lipshultz","year":"2002","unstructured":"Lipshultz SE et al (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol 20(6):1677\u20131682","journal-title":"J Clin Oncol"},{"issue":"6","key":"4637_CR28","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1542\/peds.2012-0727","volume":"130","author":"SE Lipshultz","year":"2012","unstructured":"Lipshultz SE et al (2012) Continuous versus bolus infusion of doxorubicin in children with all: long-term cardiac outcomes. Pediatrics 130(6):1003\u20131011","journal-title":"Pediatrics"},{"key":"4637_CR29","doi-asserted-by":"crossref","unstructured":"Besse HC, et al (2019) Tumor drug distribution after local drug delivery by hyperthermia, in vivo. Cancers (Basel) 11(10)","DOI":"10.3390\/cancers11101512"},{"key":"4637_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.actbio.2015.02.004","volume":"18","author":"M Sun","year":"2015","unstructured":"Sun M et al (2015) A tissue-engineered therapeutic device inhibits tumor growth in vitro and in vivo. Acta Biomater 18:21\u201329","journal-title":"Acta Biomater"},{"issue":"1","key":"4637_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/21691401.2018.1548470","volume":"47","author":"D Cao","year":"2019","unstructured":"Cao D et al (2019) Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer. Artif Cells Nanomed Biotechnol 47(1):181\u2013191","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"4637_CR32","doi-asserted-by":"crossref","unstructured":"Ahangar P, et al (2018) Nanoporous 3D-printed scaffolds for local doxorubicin delivery in bone metastases secondary to prostate cancer. Materials (Basel) 11(9)","DOI":"10.3390\/ma11091485"},{"key":"4637_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100345","volume":"26","author":"SS Phull","year":"2021","unstructured":"Phull SS et al (2021) Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: a review. J Bone Oncol 26:100345","journal-title":"J Bone Oncol"},{"key":"4637_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119048","volume":"577","author":"B Zhuang","year":"2020","unstructured":"Zhuang B et al (2020) Drug-loaded implantable surgical cavity-adaptive hydrogels for prevention of local tumor recurrence. Int J Pharm 577:119048","journal-title":"Int J Pharm"},{"key":"4637_CR35","doi-asserted-by":"crossref","unstructured":"Martin-Tellez KS, et al (2020) Isolated limb perfusion for soft tissue sarcoma: current practices and future directions. A survey of experts and a review of literature. Cancer Treat Rev 88: 102058","DOI":"10.1016\/j.ctrv.2020.102058"},{"issue":"7","key":"4637_CR36","first-page":"1703","volume":"5","author":"J Lankelma","year":"1999","unstructured":"Lankelma J et al (1999) Doxorubicin gradients in human breast cancer. Clin Cancer Res 5(7):1703\u20131707","journal-title":"Clin Cancer Res"},{"key":"4637_CR37","doi-asserted-by":"crossref","unstructured":"Ekstrom PO, et al (1997) Intratumoral differences in methotrexate levels within human osteosarcoma xenografts studied by microdialysis. Life Sci 61(19): Pl275\u201380","DOI":"10.1016\/S0024-3205(97)00839-4"},{"issue":"11","key":"4637_CR38","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1124\/dmd.111.040618","volume":"39","author":"B Achour","year":"2011","unstructured":"Achour B, Barber J, Rostami-Hodjegan A (2011) Cytochrome P450 Pig liver pie: determination of individual cytochrome P450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectrometry [corrected]. Drug Metab Dispos 39(11):2130\u20132134","journal-title":"Drug Metab Dispos"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04637-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04637-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04637-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T17:02:16Z","timestamp":1716829336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04637-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["4637"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04637-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"23 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}